Halozyme Therapeutics (NASDAQ:HALO – Free Report) had its price objective boosted by HC Wainwright from $95.00 to $115.00 in a research note issued to investors on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock.
Other analysts have also issued research reports about the stock. UBS Group reissued a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Weiss Ratings raised shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 31st. Morgan Stanley cut their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Finally, Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Nine analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $91.20.
Check Out Our Latest Research Report on Halozyme Therapeutics
Halozyme Therapeutics Stock Up 20.2%
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. The business had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a return on equity of 232.11% and a net margin of 24.86%.The firm’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, equities research analysts anticipate that Halozyme Therapeutics will post 7.54 EPS for the current year.
Insiders Place Their Bets
In other news, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total transaction of $124,653.75. Following the completion of the transaction, the director owned 42,044 shares of the company’s stock, valued at approximately $3,225,195.24. The trade was a 3.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the transaction, the director owned 14,462 shares in the company, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 72,477 shares of company stock worth $5,102,643 in the last ninety days. 2.50% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Halozyme Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Empowered Funds LLC bought a new stake in shares of Halozyme Therapeutics during the 1st quarter worth $755,000. Acadian Asset Management LLC bought a new position in Halozyme Therapeutics in the first quarter valued at $195,000. Hsbc Holdings PLC increased its stake in Halozyme Therapeutics by 117.1% in the second quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock valued at $522,000 after acquiring an additional 5,448 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in Halozyme Therapeutics by 6.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 174 shares in the last quarter. Finally, Baird Financial Group Inc. raised its position in Halozyme Therapeutics by 6.2% during the second quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after purchasing an additional 650 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.
Trending Headlines about Halozyme Therapeutics
Here are the key news stories impacting Halozyme Therapeutics this week:
- Positive Sentiment: Record Q2 results beat expectations: Halozyme reported adjusted earnings of $2.28 per share, above the roughly $1.79-$1.82 consensus, while revenue rose 48% year over year to $481 million versus estimates near $402 million. Royalty revenue increased 50% to $308 million. Halozyme reports record second quarter 2026 results
- Positive Sentiment: 2026 guidance was raised: Management now expects revenue of $1.835 billion-$1.910 billion, royalty revenue of $1.220 billion-$1.245 billion, adjusted EBITDA of $1.225 billion-$1.280 billion and non-GAAP EPS of $8.65-$9.00. The EPS range is above the approximately $8.02 analyst consensus. Halozyme Q2 earnings beat estimates
- Positive Sentiment: Commercial momentum expanded: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, exceeding its full-year goal of three. The agreements support the company’s royalty-driven platform model and broaden future revenue opportunities.
- Positive Sentiment: Analyst sentiment improved: Leerink Partners upgraded HALO to “outperform” with a $110 price target. HC Wainwright raised its target to $115 and retained a “buy” rating, while TD Cowen increased its target to $105 and also rated the stock “buy.”
- Neutral Sentiment: Analyst views remain mixed at the elevated valuation: Citizens JMP raised its target to $93 with a “market outperform” rating, and Wells Fargo lifted its target to $95 while maintaining “equal weight.” Both targets remain below the recent trading level, suggesting some analysts see limited near-term upside.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
Featured Articles
- Five stocks we like better than Halozyme Therapeutics
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
